Frank Gieseler

4.5k total citations · 1 hit paper
97 papers, 2.6k citations indexed

About

Frank Gieseler is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Frank Gieseler has authored 97 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Molecular Biology, 50 papers in Oncology and 14 papers in Hematology. Recurrent topics in Frank Gieseler's work include Cancer therapeutics and mechanisms (22 papers), Pancreatic and Hepatic Oncology Research (17 papers) and TGF-β signaling in diseases (13 papers). Frank Gieseler is often cited by papers focused on Cancer therapeutics and mechanisms (22 papers), Pancreatic and Hepatic Oncology Research (17 papers) and TGF-β signaling in diseases (13 papers). Frank Gieseler collaborates with scholars based in Germany, Canada and Austria. Frank Gieseler's co-authors include Hendrik Ungefroren, Hendrik Lehnert, Roland Kaufmann, Utz Settmacher, Fred Fändrich, Morley D. Hollenberg, Dieter Kabelitz, Daniela Wesch, Udo Kellner and Pierre Rudolph and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Frank Gieseler

95 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

2006 535 citations Volker Heinemann, D. Quietzsch et al. profile →

Peers

Countries citing papers authored by Frank Gieseler

Since Specialization

Citations

This map shows the geographic impact of Frank Gieseler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Gieseler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Gieseler more than expected).

Fields of papers citing papers by Frank Gieseler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Gieseler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Gieseler. The network helps show where Frank Gieseler may publish in the future.

Co-authorship network of co-authors of Frank Gieseler

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Gieseler. A scholar is included among the top collaborators of Frank Gieseler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Gieseler. Frank Gieseler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells 2024 ·Cell Communication and Signaling ·(unknown), (unknown), Mario W. Kramer, Axel S. Merseburger, Sivahari Prasad Gorantla, Matthias Klinger, (unknown), (unknown), Timo Gemoll, Nikolas von Bubnoff, Frank Gieseler, Masoud Darabi	3
2	SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group 2023 ·Annals of Oncology ·(unknown), Volker Heinemann, Laura Fischer, Frank Gieseler, Thomas Hoehler, Julia Mayerle, D. Quietzsch, Anke Reinacher‐Schick, Michael Schenk, G. Seipelt, Jens T. Siveke, Michael Stahl, Ursula Vehling‐Kaiser, Dirk Waldschmidt, Klara Dorman, (unknown), C. Benedikt Westphalen, Michael Haas, Stefan Boeck	1
3	An update on the secretory functions of brown, white, and beige adipose tissue: Towards therapeutic applications 2023 ·Reviews in Endocrine and Metabolic Disorders ·Zeinab Ghesmati, (unknown), Shabnam Fayezi, Frank Gieseler, Effat Alizadeh, Masoud Darabi	53
4	Physicians’ perspectives on family caregivers’ roles in elderly cancer patients’ therapies: a qualitative, interview-based study 2023 ·Supportive Care in Cancer ·(unknown), Susanne Elsner, (unknown), Joachim Hübner, Christina Schües, Christoph Rehmann‐Sutter, Alexander Katalinic, Frank Gieseler	3
5	Contributing and limiting factors to guideline-adherent therapy in senior and elderly breast cancer patients: a questionnaire-based cross-sectional study using clinical and cancer registry data in Germany 2023 ·Journal of Cancer Research and Clinical Oncology ·(unknown), (unknown), Susanne Elsner, Frank Gieseler, Alexander Katalinic, Joachim Hübner	1
6	RAC1B Suppresses TGF-β1-Dependent Cell Migration in Pancreatic Carcinoma Cells through Inhibition of the TGF-β Type I Receptor ALK5 2019 ·Cancers ·Hendrik Ungefroren, (unknown), Christian Fiedler, Koichiro Mihara, Morley D. Hollenberg, Frank Gieseler, Hendrik Lehnert, David P. Witte	20
7	PO-18 - Fibronectin EDA/EDB is expressed in adherent SCLC NCI-H69 cells and in pleural effusions of lung cancer patients: possible implication for drug resistance 2016 ·Thrombosis Research ·(unknown), M. Heiden, Rainer Seitz, Frank Gieseler	2
8	Obesity and cancer 2015 ·Hormone Molecular Biology and Clinical Investigation ·Hendrik Ungefroren, Frank Gieseler, Stephanie Fliedner, Hendrik Lehnert	35
9	Pluripotency Gene Expression and Growth Control in Cultures of Peripheral Blood Monocytes during Their Conversion into Programmable Cells of Monocytic Origin (PCMO): Evidence for a Regulatory Role of Autocrine Activin and TGF-β 2015 ·PLoS ONE ·Hendrik Ungefroren, Ayman Hyder, (unknown), Stephanie Groth, Hans Lange, Karim M. Fawzy El‐Sayed, Sabrina Ehnert, Andreas K. Nüssler, Fred Fändrich, Frank Gieseler	6
10	Correction: Characterization of Spontaneous and TGF-β-Induced Cell Motility of Primary Human Normal and Neoplastic Mammary Cells In Vitro Using Novel Real-Time Technology 2013 ·PLoS ONE ·Katharina Mandel, Daniel Seidl, Dirk Rades, Hendrik Lehnert, Frank Gieseler, Ralf Hass, Hendrik Ungefroren	5
11	Characterization of Spontaneous and TGF-β-Induced Cell Motility of Primary Human Normal and Neoplastic Mammary Cells In Vitro Using Novel Real-Time Technology 2013 ·PLoS ONE ·Katharina Mandel, Daniel Seidl, Dirk Rades, Hendrik Lehnert, Frank Gieseler, Ralf Hass, Hendrik Ungefroren	36
12	The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells 2012 ·Cancer Chemotherapy and Pharmacology ·Tobias Bartscht, Hendrik Lehnert, Frank Gieseler, Hendrik Ungefroren	28
13	Toll-like Receptors 3 and 7 Agonists Enhance Tumor Cell Lysis by Human γδ T Cells 2009 ·Cancer Research ·(unknown), Hans‐Heinrich Oberg, (unknown), Lothar Marischen, (unknown), Christoph Mundhenke, Frank Gieseler, Dieter Kabelitz, Daniela Wesch	81
14	Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail? 2003 ·International Journal of Colorectal Disease ·Frank Gieseler, P. Rudolph, (unknown), Ulrich R. Foelsch	28
15	Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage 1999 ·Leukemia ·Frank Gieseler, Eckhard Bauer, V. Nuessler, Melody S. Clark, (unknown)	33
16	Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression 1997 ·Annals of Hematology ·V. Nüßler, Frank Gieseler, H. Zwierzina, (unknown), R. Pelka‐Fleischer, Heinz Diem, (unknown), Roland Schmitt, Irmgard Langenmayer, (unknown), H. Kolb, W. Wilmanns	9
17	Different Functional States of Topoisomerase II can be Discriminated by Orthovanadate Sensitivity in Multi-drug Resistant Human Leukemic Cells 1993 ·Leukemia & lymphoma ·Fritz Boege, Frank Gieseler, Harald Biersack, (unknown)	2
18	A drug‐resistant variant of topoisomerase IIα in human HL‐60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub‐nuclear distribution 1993 ·European Journal of Biochemistry ·Fritz Boege, Eigil Kjeldsen, Frank Gieseler, Jan Alsner, Harald Biersack	11
19	Alteration of topoisomerase II action is a possible molecular mechanism of HL-60 cell differentiation. 1990 ·Environmental Health Perspectives ·Frank Gieseler, Fritz Boege, Melody S. Clark	10
20	Granulocytic differentiation of HL-60 cells is not regulated by DNA de novo methylation 1989 ·Annals of Hematology ·Frank Gieseler, Peter Meyer, Dietmar Schiffmann, Klaus Wilms	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact